$599

Invokana Receives Positive CHMP Opinion for CV Indication

Janssen announced CHMP has granted a positive opinion to update the Invokana and Vokanamet labels to include data on the reduction of 3P-MACE in patients with T2DM and a history of CVD or at least 2 risk factors.

This content is for Read Less members only.
Register
Already a member? Log in here